Latest PhosLo Stories
~Launches "Keryx Patient Plus" for Reimbursement Support and Patient Access NEW YORK, Dec. 22, 2014 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc.
Study will evaluate tenapanor for the treatment of hyperphosphatemia in ESRD patients on hemodialysis FREMONT, Calif., May 15, 2014 /PRNewswire/ -- Ardelyx, Inc., a clinical-stage
EXTON, Pa., April 29 /PRNewswire/ -- BioTrends Research Group, Inc. recently published two syndicated reports focused on the management of bone and mineral metabolism in the US.
NEW YORK, Sept. 23 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc.
NEW YORK, June 8 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc.
PHILADELPHIA, April 3, 2008 /PRNewswire/ -- Shire Pharmaceuticals, the global biopharmaceutical company, today announced the launch of On Track, an innovative program designed to improve adherence to disease management regimens among chronic kidney disease (CKD) Stage 5 patients with hyperphosphatemia (elevated levels of phosphorus in the blood).
- Emitting flashes of light; glittering.